Poo JL, Muñoz LE

Language: English
References: 4
Page: 845-846
PDF size: 47.49 Kb.

ABSTRACT

To the editor:

Once considered irreversible, there are well-documented cases of reversibility of liver cirrhosis,¹ which has stimulated evaluation of antifibrotic drugs such as pirfenidone.²

REFERENCES

1. Flores-Contreras L, Sandoval-Rodríguez A, Mena-Enriquez M, Lucano-Landeros S, Arellano-Olivera I, Alvarez- Alvarez A, Sánchez-Parada G, et al. Treatment with Poo JL, et al. , 2014; 13 (6): 845-846 846 pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterology 2014; 14: 131-41.

2. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. The Journal of Clinical Investigation 2013; 123: 1887-901.

3. Xaubet A, Serrano-Mollar A, Ancochea J. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert opinion on pharmacotherapy 2014: 1-7.

4. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 740-7.